Abstract: The present application provides materials and methods for controlling gene editing. The present application also provides materials and methods for controlling transcriptional expression of guide RNAs and/or post-transcriptional expression of Cas nuclease.

Abstract: Provided is a fully aromatic ether ketone resin composition including: (A) a fully aromatic ether ketone resin; and (B) a phosphorus stabilizer, in which (B) the phosphorus stabilizer contains (B1) a dihydrogen phosphate and (B2) a hydrogen phosphate, (B1) the dihydrogen phosphate is one or more dihydrogen phosphates of alkali metals or one or more dihydrogen phosphates of alkaline earth metals and the like, (B2) the hydrogen phosphate is one or more hydrogen phosphates of alkali metals or one or more hydrogen phosphates of alkaline earth metals and the like, (B1) the dihydrogen phosphate and (B2) the hydrogen phosphate are contained in a predetermined combination, and a total amount of (B) the phosphorus stabilizer is 100 to 5000 mass ppm.

Abstract: Provided herein are novel thermostable phycobiliproteins. These proteins may be stabilized by the introduction of disulfide bonds which stabilize the protein. Modified cells expressing these thermostable phycobiliproteins and methods of making them are also provided.

Abstract: The present application provides materials and methods for treating a patient with autosomal dominant RP, both ex vivo and in vivo; materials and methods for editing a RHO gene in a human cell; and materials and methods for editing a P23H mutation in a RHO gene in a human cell. In addition, the present application provides one or more gRNAs or sgRNAs for editing a RHO gene; one or more gRNAs or sgRNAs for editing a P23H mutation in a RHO gene; and a therapeutic comprising at least one or more gRNAs or sgRNAs for editing a P23H mutation in a RHO gene. The present application provides a therapeutic for treating a patient with autosomal dominant RP. The present application provides a kit for treating a patient with autosomal dominant RP. In addition, the present application provides a self-inactivating CRISPR-Cas system.

Abstract: This disclosure describes techniques for creating stable, targeted mutations in Spirulina (Athrospiria) and Spirulina having stable, targeted mutations.

Abstract: Aspects of this invention, inter alia, relate to novel systems for targeting, editing or manipulating DNA in a cell, using novel synthetic RNA-guided nucleases (sRGNs). The sRGNs are derived from wildtype or parental small type II CRISPR Cas9 endonucleases.

Abstract: The present application provides a CRISPR/Cas system comprising a nuclease segment that encodes a Cas9 nuclease or variant thereof, a guide RNA segment comprising a nucleotide sequence that encodes a gRNA or sgRNA, and a promoter segment comprising a nucleotide sequence that encodes a first promoter comprising one or more tetracycline operator sequence, wherein the gRNA segment is operably linked to the promoter segment. The present application also provides materials and methods for controlling transcriptional expression of guide RNAs and/or post-transcriptional expression of Cas nuclease.

Abstract: Provided is a fully aromatic ether ketone resin composition including: (A) a prescribed fully aromatic ether ketone resin; and (B) a salt composed of an acid and a base, in which a pH thereof obtained by performing measurement by means of a pH measurement method below is 6 to 8. [pH measurement method] (a) To 10 g of a powder of the fully aromatic ether ketone resin composition, 5 mL of acetone is added, then 100 mL of pure water is added thereto, a mixture is stirred for 10 minutes, and then the mixture is subjected to filtration. (b) 0.1 mL of pure water is added dropwise to a residue obtained by volatilizing a liquid component of a filtrate obtained. (c) A temperature is set to 25° C., and the pH is measured by contacting a pH test paper with the pure water added dropwise.

Abstract: The present application relates to, inter alia, compositions including proteins for expression in host cells to render them resistant to rapamycin. The application further relates to methods of using the proteins, cells, and compositions disclosed therein for modulating cell signaling and for selective expansion of cells.

Abstract: This disclosure describes techniques for creating stable, targeted mutations in Spirulina (Arthrospira) and Spirulina having stable, targeted mutations.

Abstract: The present application relates to, inter alia, compositions including proteins for expression in host cells to render them resistant to rapamycin. The application further relates to methods of using the proteins, cells, and compositions disclosed therein for modulating cell signaling and for selective expansion of cells.

Abstract: An object of the present invention is to provide an exhaust gas purification catalyst composition and an exhaust gas purification catalyst, each of which includes a pyrochlore-type CeO2—ZrO2-based complex oxide having an improved oxygen storage capacity (particularly, an improved oxygen storage capacity after being exposed to a high temperature environment), and, in order to achieve the above-mentioned object, the present invention provides an exhaust gas purification catalyst composition and an exhaust gas purification catalyst, each of which contains a pyrochlore-type CeO2—ZrO2-based complex oxide that contains Y and Mg and thus exhibits an excellent oxygen storage capacity (particularly, an excellent oxygen storage capacity after being exposed to a high temperature environment).

Abstract: An object of the present invention is to provide an exhaust gas purification catalyst composition and an exhaust gas purification catalyst, each of which includes a pyrochlore-type CeO2—ZrO2-based complex oxide having an improved oxygen storage capacity (particularly, an improved oxygen storage capacity after being exposed to a high temperature environment), and, in order to achieve the above-mentioned object, the present invention provides an exhaust gas purification catalyst composition and an exhaust gas purification catalyst, each of which contains a pyrochlore-type CeO2—ZrO2-based complex oxide that contains Y and Mg and thus exhibits an excellent oxygen storage capacity (particularly, an excellent oxygen storage capacity after being exposed to a high temperature environment).

Abstract: According to one embodiment, an electronic device includes a power-supply voltage input terminal, a first capacitor, and a second capacitor. The first capacitor has a fixed capacitance. The second capacitor has a variable capacitance. The first capacitor and the second capacitor are connected in parallel to the power-supply voltage input terminal.

Abstract: Provided herein are novel thermostable phycobiliproteins. These proteins may be stabilized by the introduction of disulfide bonds which stabilize the protein. Modified cells expressing these thermostable phycobiliproteins and methods of making them are also provided.

Abstract: The present application provides materials and methods for treating a patient with autosomal dominant CORD, both ex vivo and in vivo; materials and methods for editing a GUCY2D gene in a human cell; and materials and methods for editing a R838H, R838C, or R838S mutation in a GUCY2D gene in a human cell. The present application also provides one or more gRNAs or sgRNAs for editing a GUCY2D gene; one or more gRNAs or sgRNAs for editing a R838H, R838C, or R838S mutation in a GUCY2D gene; and a therapeutic comprising at least one or more gRNAs or sgRNAs for editing a R838H, R838C, or R838S mutation in a GUCY2D gene. The present application provides a therapeutic for treating a patient with autosomal dominant CORD. The present application also provides a kit for treating a patient with autosomal dominant CORD. In addition, the present application provides a self-inactivating CRISPR-Cas system.

Abstract: The present application relates to, inter alia, compositions including proteins for expression in host cells to render them resistant to rapamycin. The application further relates to methods of using the proteins, cells, and compositions disclosed therein for modulating cell signaling and for selective expansion of cells.

Abstract: According to one embodiment, an electronic device includes a power-supply voltage input terminal, a first capacitor, and a second capacitor. The first capacitor has a fixed capacitance. The second capacitor has a variable capacitance. The first capacitor and the second capacitor are connected in parallel to the power-supply voltage input terminal.

Abstract: A memory system includes a non-volatile memory having a plurality of memory chips, a plurality of switches provided for each of the memory chips for switching on and off supply of power to the corresponding memory chip, and a memory controller configured to control the switches and data access to the non-volatile memory. The memory controller is further configured to determine whether there is a first memory chip among the plurality of memory chips that has no data item stored therein with an elapsed time from a most recent access thereof that is less than a threshold value, and if so, turn off the supply of power to the first memory chip while maintaining the supply of power to the plurality of memory chips other than the first memory chip.

Abstract: The present application provides materials and methods for treating a patient with autosomal dominant CORD, both ex vivo and in vivo; materials and methods for editing a GUCY2D gene in a human cell; and materials and methods for editing a R838H, R838C, or R838S mutation in a GUCY2D gene in a human cell. The present application also provides one or more gRNAs or sgRNAs for editing a GUCY2D gene; one or more gRNAs or sgRNAs for editing a R838H, R838C, or R838S mutation in a GUCY2D gene; and a therapeutic comprising at least one or more gRNAs or sgRNAs for editing a R838H, R838C, or R838S mutation in a GUCY2D gene. The present application provides a therapeutic for treating a patient with autosomal dominant CORD. The present application also provides a kit for treating a patient with autosomal dominant CORD. In addition, the present application provides a self-inactivating CRISPR-Cas system.